FANJ
HRTX icon

Financial Architects (New Jersey)’s Heron Therapeutics HRTX Stock Holding History

Financial Architects (New Jersey)’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-300
Closed -$8K – 1397
2018
Q1 		$8K Buy
+300
New +$6.8K ﹤0.01% 1147
2017
Q3 		– Sell
-40
Closed -$1K – 1524
2017
Q2 		$1K Hold
40
– – ﹤0.01% 1475
2017
Q1 		$1K Hold
40
– – ﹤0.01% 1515
2016
Q4 		$1K Sell
40
-20
-33% -$314 ﹤0.01% 1348
2016
Q3 		$1K Buy
+60
New +$1.11K ﹤0.01% 1409

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Financial Architects (New Jersey)'s HRTX Position: Q2 2018 in Review

Financial Architects (New Jersey) sold out of Heron Therapeutics (HRTX) in Q2 2018, closing a stake of 300 shares — an estimated $8K sold.

Financial Architects (New Jersey) first reported a position in HRTX in Q3 2016 and held it in 5 quarters. The position peaked at $8K in Q1 2018. 196 funds tracked by Wall St. Rank hold HRTX as of Q2 2018.

  • Financial Architects (New Jersey) reported no remaining Heron Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 300 Heron Therapeutics shares in Q2 2018, an estimated $8K.
  • Financial Architects (New Jersey) first reported a position in Heron Therapeutics in Q3 2016 and held it in 5 quarters.
  • Financial Architects (New Jersey)'s Heron Therapeutics position peaked at $8K in Q1 2018.
  • 196 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2018, filed 3 Aug 2018.